NYSE:NVOPharmaceuticals
Novo Nordisk Oral Wegovy Launch Reshapes Obesity Access And Valuation Outlook
Novo Nordisk (NYSE:NVO) has launched an FDA approved oral version of its obesity drug Wegovy, expanding its GLP 1 obesity treatment portfolio.
The company is working with consumer outlets such as Amazon and Costco to widen distribution and patient access.
Novo Nordisk plans to integrate Catalent's U.S. fill finish site to roughly double its domestic supply chain capacity for obesity treatments.
Novo Nordisk, known for its diabetes and obesity treatments, now adds an oral Wegovy option that...